These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38092720)

  • 1. De novo Donor-specific Anti-human Leukocyte Antigen Antibody and Its Outcome in Pediatric Renal Transplant Recipients: A Single-center Experience in India.
    Saha A; Kapadia SF; Vala KB; Trivedi VB; Patel HV; Shah PR; Kute VB
    Saudi J Kidney Dis Transpl; 2023 Jan; 34(1):87-95. PubMed ID: 38092720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients.
    Brokhof MM; Sollinger HW; Hager DR; Muth BL; Pirsch JD; Fernandez LA; Bellingham JM; Mezrich JD; Foley DP; D'Alessandro AM; Odorico JS; Mohamed MA; Vidyasagar V; Ellis TM; Kaufman DB; Djamali A
    Transplantation; 2014 Mar; 97(6):612-7. PubMed ID: 24531846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human leukocyte antigen compatibility and incidence of donor-specific antibodies in pediatric liver transplant recipients.
    Melere MU; Feier FH; Neumann J; Kalil AN; Montagner JM; Nader LS; da Silva CS; Junior MAF; Coral GP; Bobsin GP; Ferreira CT
    World J Gastroenterol; 2024 Sep; 30(33):3837-3845. PubMed ID: 39351427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Utility of Donor-specific Antibody Monitoring and the Role of Kidney Biopsy in Simultaneous Liver and Kidney Recipients With De Novo Donor-specific Antibodies.
    Parajuli S; Aziz F; Blazel J; Muth BL; Garg N; Mohamed M; Rice J; Mezrich JD; Hidalgo LG; Mandelbrot D
    Transplantation; 2021 Jul; 105(7):1548-1555. PubMed ID: 32732618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies.
    Steggerda JA; Kim IK; Haas M; Zhang X; Kang A; Pizzo H; Kamil E; Jordan S; Puliyanda D
    Pediatr Transplant; 2017 Dec; 21(8):. PubMed ID: 29159992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and outcomes of de novo donor-specific antibodies in low, moderate, and high immunological risk kidney transplant recipients.
    Wan SS; Chadban SJ; Watson N; Wyburn K
    Am J Transplant; 2020 May; 20(5):1351-1364. PubMed ID: 31867849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between human leukocyte antigen eplet mismatches, de novo donor-specific antibodies, and the risk of acute rejection in pediatric kidney transplant recipients.
    Sharma A; Taverniti A; Graf N; Teixeira-Pinto A; Lewis JR; Lim WH; Alexander SI; Durkan A; Craig JC; Wong G
    Pediatr Nephrol; 2020 Jun; 35(6):1061-1068. PubMed ID: 32065279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of persistent preformed and de novo donor-specific antibodies detected at 1 year after kidney transplantation on long-term graft survival in Japan: a retrospective study.
    Fujiyama N; Satoh S; Saito M; Numakura K; Inoue T; Yamamoto R; Saito T; Kanda S; Narita S; Mitobe Y; Habuchi T
    Clin Exp Nephrol; 2019 Dec; 23(12):1398-1406. PubMed ID: 31493185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
    Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
    Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
    PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
    Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
    Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies.
    Marfo K; Ajaimy M; Colovai A; Kayler L; Greenstein S; Lubetzky M; Gupta A; Kamal L; de Boccardo G; Masiakos P; Kinkhabwala M; Akalin E
    Transplantation; 2014 Nov; 98(10):1082-8. PubMed ID: 24873780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes.
    Wiebe C; Pochinco D; Blydt-Hansen TD; Ho J; Birk PE; Karpinski M; Goldberg A; Storsley LJ; Gibson IW; Rush DN; Nickerson PW
    Am J Transplant; 2013 Dec; 13(12):3114-22. PubMed ID: 24164958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant de novo non donor-specific HLA antibodies are not associated with poor graft outcome in non-sensitized pediatric recipients of kidney transplantation.
    Cioni M; Comoli P; Tagliamacco A; Innocente A; Basso S; Fontana I; Magnasco A; Trivelli A; Nocco A; Macchiagodena M; Catenacci L; Klersy C; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Nocera A
    Transpl Immunol; 2021 Apr; 65():101375. PubMed ID: 33610675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
    Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD
    Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients.
    Charnaya O; Jones J; Philogene MC; Chiang PY; Segev DL; Massie AB; Garonzik-Wang J
    Pediatr Nephrol; 2021 Dec; 36(12):3971-3979. PubMed ID: 34100108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies.
    Ixtlapale-Carmona X; Arvizu A; De-Santiago A; González-Tableros N; López M; Castelán N; Marino LA; Uribe-Uribe NO; Contreras AG; Vilatobá M; Morales-Buenrostro LE; Alberú J
    Transpl Immunol; 2018 Feb; 46():8-13. PubMed ID: 28974434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
    Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
    Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.